NCT01093807

Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension

Randomized, Parallel Group, Double-blind Trial to Evaluate Different Dose Combinations of Lercanidipine and Enalapril in Comparison With Each Component Administered Alone and With Placebo in Patients With Essential Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1,039 (actual)
• Sponsor: RECORDATI GROUP · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of various dosage combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with their respective components and with placebo.

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	Placebo	once daily for 10 weeks
DRUG	Lercanidipine	10 mg once daily for 10 weeks
DRUG	Lercanidipine	20 mg once daily for 10 weeks
DRUG	Enalapril	10 mg once daily for 10 weeks
DRUG	Enalapril	20 mg once daily for 10 weeks
DRUG	Lercanidipine + Enalapril	10/10 mg once daily for 10 weeks
DRUG	Lercanidipine + Enalapril	10/20 mg once daily for 10 weeks
DRUG	Lercanidipine + Enalapril	20/10 mg once daily for 10 weeks
DRUG	Lercanidipine + Enalapril	20/20 mg once daily for 10 weeks

Timeline

• Start date: 2010-03-01
• Primary completion: 2011-03-01
• Completion: 2011-04-01
• First posted: 2010-03-26
• Last updated: 2011-04-29

Locations

1 site across 1 country: France